期刊文献+

非ST段抬高型急性冠脉综合征患者药物治疗前后血浆B型尿钠肽水平变化及其与冠脉病变程度的关系分析 被引量:6

Analysis of BNP level of patients with non-ST-elevationacute coronary syndrome before and after medication and their correlation with the severity of coronary lesions
下载PDF
导出
摘要 目的 观察非ST段抬高型急性冠脉综合征(NSTE-ACS)患者药物治疗前后血浆B型尿钠肽(BNP)水平的变化,及BNP水平与冠脉病变程度的关系,及其对近期预后的判断价值.方法 选取2012年6月~2013年6月河北大学附属医院心内1科不稳定型心绞痛及NSTE-ACS且心功能正常的患者98例为研究对象,将其分为不稳定性心绞痛组(A组)48例,NSTE-ACS组(B组)50例.检测并比较两组患者入院时及治疗48 h前后BNP水平,分析入院BNP水平与冠脉病变程度的相关性,及BNP水平与出院3个月内心血管不良事件发生的关系.结果 入院时B组BNP水平明显高于A组[(417.69±86.74)ng/L比(167.23±66.83)ng/L],差异有统计学意义(P<0.05);治疗前A、B两组患者BNP水平[(167.23±66.83)ng/L、(417.69±86.74)ng/L]均高于治疗后[(85.29±23.62) ng/L、(184.12±48.96)ng/L,差异均有统计学意义(均P< 0.05);冠状动脉3支与2支病变组BNP水平[(475.97±86.44)、(335.33±88.66)ng/L]明显高于1支病变组[(142.08±54.09) ng/L],差异均有统计学意义(均P<0.05);随着BNP水平的升高,3个月的心血管事件发生率有升高趋势(P<0.05).结论 BNP水平与心肌缺血程度密切相关,故测定外周血BNP水平对于判断冠状动脉严重程度及预测心血管不良事件有重要价值. Objective To investgate the change of B-type natriuretic peptide (BNP) level of patients with non-ST-elevation coronary syndromes (NSTE-ACS) before and after medication,their correlation with the severity of coronary lesions,and the evaluate value of early prognostic.Methods A total of 98 patients who were diagnosed as unstable angina pectoris and NSTE-ACS without heart failure in First Cardiovascular Medicine Department of the Affiliated Hospital of Hebei University were selected as study objects,and they were divided into unstable angina pectoris group (group A)with 48 cases and NSTE-ACS group (group B) with 50 cases.The BNP level of two groups on admission and after 48 hours of medication were recorded and compared; the relationship between the BNP level on admission and severity of coronary lesions was analyzed.Results The BNP level of group B was higher than that of group A [(417.69±86.74) ng/L vs (167.23±66.83) ng/L],the difference was statistically significant (P 〈 0.05); the BNP level of group A and B before medication [(167.23±66.83) ng/L,(417.69±86.74) ng/L] were obviously higher than those after medication [(85.29±23.62) ng/L,(184.12±48.96) ng/L],the differences were statistically significant (all P 〈 0.05),The level of BNP in 2 and 3 vessels lesion group [(475.97±86.44),(335.33±88.66) ng/L] were higher than those in 1 vessel lesion group [(142.08±54.09) ng/L],the differences were statistically significant (all P 〈 0.05).With the increasing of the BNP levels,the incidence of cardiovascular event showed upward tendency (P 〈 0.05).Conclusion The ischemia degree of cardiac muscle is closely correlated with the BNP level,the concentration of BNP in Peripheral blood plays an important role in assessing the degree of coronary lesions and calculating cardiovascular event.
出处 《中国医药导报》 CAS 2014年第8期147-149,154,共4页 China Medical Herald
关键词 非ST段抬高型急性冠脉综合征 BNP 药物治疗 Non-ST-elevation coronary syndromes B-type natriuretic peptide Medication
  • 相关文献

参考文献12

  • 1Iwanaga Y,Nishi I,Furuichi S,et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure comparison between systolic and diastolic heart failure [J]. J Am Coil Cardiol, 2006,47 (4): 742-748.
  • 2刘北,付强,严全能,靳文,陶丹萍,华经海,李志樑.联合检测生化标志物在急性冠脉综合症早期危险分层中的意义[J].南方医科大学学报,2010,30(5):1015-1019. 被引量:26
  • 3Goetze JP, Gore A ,Moller CH ,et al. Acute myocardial hy- poxia increaseer BNP gene expression [J]. FA SEB J, 2004, 189(15) : 1928-1930.
  • 4Krishnaswamy P, Lubien E, Clopton P, et al. Utitlity of B- natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfuntion [J]. Am J Med, 2001,111 (4) :274.
  • 5Morrow DA, Lemons JA, Blazing MA, et al. Prognostic val- ue of serial B-type natriuretic peptide testing during fol low-up of patients with unstable coronary artery disease [J]. JAMA, 2005,294 (22) : 2866-2871.
  • 6Palazzuoli A, Deckers J, Calabro A, et al. Brain natriuretic peptide and other risk markers for outcom assessment in patients with non-ST-elevation coronary syndromes and preserved systolic function [J].Am J Cardiol,2006,98 (10) : 1322-1328.
  • 7Sinclair H, Paterson M, Warks S, et al. Predicting outcome in patients with acute coronary syndrome : evaluation of B- type natriuretic peptide and the global registry of acute coronary events (GRACE)risk score [J]. Scott Med J, 2007,52(3) :8-13.
  • 8Lemos JA,Morrow DA,Bentley JH,et al. The prognostic value of B-type natriu-retic peptide in patients with acute coronary syndromes [J]. N Engl J Med,2001,345 (14): 1014-1021.
  • 9Niizuma S, Iwanaga Y, Yahata T, et al. Plasma B-type na- triuretic peptide levels reflect the presence and severity of stable coronary artery disease in chronic haemodialysis patients [J]. NDP,2009,24(2):597-603.
  • 10Hopkins WE ,Chen Z, Fukagawa NK,et al. Increased atri- al and brain natriureticpep-tide in adults with cyanotic congenial heart disease [J]. Circulation, 2004,109 (23) : 2866-2872.

二级参考文献27

  • 1高伟,王士雯.蛋白质组技术在心血管病研究中的应用现状[J].中华心血管病杂志,2004,32(11):1047-1049. 被引量:3
  • 2Lucas AL, Korol R, Pepine CJ. Inflammation in atherosclerosis: some thoughts about the acute coronary syndromes [J ]. Circulation, 2006, 113: e728-e732.
  • 3Apple FS, Pearce LA, Chung A, et al. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome [J]. Clin Chem, 2007, 53: 874-81.
  • 4Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome [J ]. Clin Chem, 2005, 51: 810-24.
  • 5Thim T, Hagensen MK, Bentzon JF, et al. From vulnerable plaque to atherothrombosis[J ]. J Intern Med, 2008, 263(5): 506-16.
  • 6Bassand JP, Harem CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes[J]. Eur Heart J, 2007, 28: 1598-660.
  • 7TIM/IIIB investigators effects of tissue plasrninogen activator and comparison of early Invasive and conservative st rategies in unstable angina and Non-Q-wave myocardial infraction. Results of the TIMI IIIB[J]. Circulation, 1994, 89: 1545-56.
  • 8Spacek R,Widimsky P, Straka Z, et al. Value of first day angiography/ angioplasty in evolving non-ST segment elevation myocardial infarction: an open multieenter randomized trial. The V INO Study [J]. Eur Heart J, 2002, 23: 230-8.
  • 9Tousoulis D, Kampoli AM, Stefanadi E, et al. New biochemical markers in acute coronary syndrome[J]. Cttrr Med Chem, 2008, 15: 1288-96.
  • 10Brerman ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain [J]. N Engl J Med, 2003, 349: 1595-604.

共引文献25

同被引文献51

  • 1魏鹏,付强,白洁,陶志文.急性冠状动脉综合征患者B型钠尿肽和应激血糖水平变化及与冠状动脉病变程度关系[J].中华临床医师杂志(电子版),2011,5(21):6251-6255. 被引量:8
  • 2李健,邓兵,刘爱莉,刘如辉,郑黎强.急诊经皮冠状动脉干预术治疗急性冠脉综合征患者血B-型尿钠肽的变化特点[J].中华急诊医学杂志,2007,16(10):1081-1085. 被引量:1
  • 3Keles N,Kalcik M,Caliskan M,et al.The effects of urgent percutaneous coronary intervention on right ventricular systolic functions in non-ST-elevation acute coronary syndromes. Interv Med Appl Sci . 2015
  • 4Dehghani MR,Rezaei Y,Taghipour-Sani L.White blood cell count to mean platelet volume ratio as a novel noninvasive marker predicting long-term outcomes in patients with non-ST elevation acute coronary syndrome. Cardiol J . 2015
  • 5Barros V,Pereira M,Araújo C,et al.Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal:the EURHOBOP study. Revista Portuguesa de Cardiologia . 2015
  • 6Widimsky P,Motovska Z,Bolognese L,et al.Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart . 2015
  • 7Chang ST,Chung CM,Chu CM,et al.Platelet Glycoprotein IIb/IIIa Inhibitor Tirofiban Ameliorates Cardiac Reperfusion Injury. Int Heart J . 2015
  • 8Eyüboˇglu M.What is the real predictive value of red cell distribution width for the mortality in non-ST elevation acute coronary syndrome?. Anatol J Cardiol . 2015
  • 9Puri A,Bansal A,Narain VS,et al.Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI. Indian Heart . 2013
  • 10Liu Y,Liu H,Hao Z,et al.Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI). Int J Clin Exp Med . 2015

引证文献6

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部